Sanofi and GSK expected to have definitive results for their long-delayed coronavirus vaccine by now, having redesigned their shot after an initial formulation disappointed late …

Agency advisers had opposed a broad booster dose clearance in September, leading the FDA to limit use to older adults and those at high risk …

J&J has recorded far fewer sales of its coronavirus vaccine than competitors Pfizer and Moderna, partly due to its not-for-profit pricing but also to a …

After months sticking with its coronavirus vaccine, CureVac has finally given up. CureVac executives had long argued the shot could still play a role in …

For the past several months, one of the many questions hanging over the booster debate has ben what do with people who got J&J’s shot. …

While not acknowledged directly, the “corresponding changes in demand” could also stem from disappointing clinical trial results CureVac released for its vaccine in mid-June, which …

The Food and Drug Administration on Monday granted full approval to Pfizer and BioNTech’s coronavirus vaccine, a long-awaited decision that government officials hope could help …